Developer docs
API playgroundTry for free, no card

Search company profiles

InClin, Inc

Full company profile

uuid000b2f1

Namestring
InClin, Inc
Legal namestring
InClin, Inc.
Websiteurl
inclin.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

InClin, Inc. is a privately-held, full-service Contract Research Organization (CRO) founded in 1998 that delivers clinical research services to biotechnology and pharmaceutical sponsors from Phase 1 through Phase 4. The company operates from a San Mateo, California headquarters and a wholly-owned Australian subsidiary (InClin PTY LTD) in North Sydney, providing regional coverage in North America and the Asia-Pacific. Its customer base spans small biotech startups and enterprise pharmaceutical sponsors, with documented experience executing multinational registrational trials across up to 36 countries and 291 sites, including programs that have achieved NDA and EMA approvals.

The service portfolio covers Biometrics (data management, statistical analysis, CDISC-compliant SDTM/ADaM dataset development, and PK/PD analyses using Phoenix WinNonLin), Clinical Operations (project management, monitoring, feasibility, and Trial Master File management via Veeva Vault), Strategic Consulting, Medical Writing, Quality Assurance, Clinical Drug Safety and Pharmacovigilance (anchored on the Argus Safety database), and Medical Monitoring. The technology stack is built entirely on industry-standard third-party platforms rather than proprietary systems; differentiation is positioned on staff quality (averaging 20+ years of clinical research experience) and a regulatory track record that includes 3 successful NDA approvals and multiple FDA/EMA inspections with no 483 observations.

InClin generates revenue through custom professional services contracts on multi-year engagements. The go-to-market is sales-led, with direct business development outreach, quote-based pricing per engagement, and services contracted either as integrated single-source solutions or as standalone modules. The company is founder-owned: co-founders Arnold G. Wong (CFO) and Taylor T. Kilfoil (Chief International Officer) remain in active leadership roles alongside CEO Brian A. Horger, PhD (formerly of Genentech, Theravance Biopharma, and Covance Early Clinical Services). No external institutional investors, private equity backing, or parent company ownership is indicated in available data.

Short descriptiontext

InClin is a privately-held, full-service Contract Research Organization founded in 1998, providing Phase 1 through Phase 4 clinical research services (biometrics, clinical operations, drug safety, medical writing, QA, and monitoring) to biotech and pharmaceutical sponsors from offices in San Mateo, California and Sydney, Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, clinical trial services, biometrics and statistics, pharmacovigilance services, medical writing
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Contract Research Organization (CRO) Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

InClin generates revenue as a full-service CRO providing integrated clinical research services from Phase 1 through Phase 4. Revenue is derived from service fees for biometrics, clinical operations, strategic consulting, medical writing, quality assurance, drug safety, and medical monitoring services. Services can be contracted as comprehensive single-source solutions or as standalone service modules.

inclin.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom CRO service contracts
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed. InClin provides tailored service offerings as standalone modules or integrated single-source solutions. Prospective clients contact BusDev@InClin.com for service inquiries.

inclin.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

InClin is a full-service Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to manage Phase 1 through Phase 4 clinical trials. The company delivers integrated single-source solutions or standalone services spanning biometrics, clinical operations, strategic consulting, medical writing, quality assurance, drug safety and pharmacovigilance, and medical monitoring for drug development sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3 successful NDA approvals for Phase 1-3 clinical development programs
+3 more records
Product overview1 text field

InClin is a full-service Contract Research Organization (CRO) founded in 1998, offering an integrated suite of clinical research services from Phase 1 through Phase 4. The company operates as a single-source solution combining Biometrics, Clinical Operations, Strategic Consulting, Medical Writing, Quality Assurance, Clinical Drug Safety and Pharmacovigilance, and Medical Monitoring services. These core offerings work together as an integrated solution or can be engaged as standalone services to support biotech and pharmaceutical companies through the complete drug development lifecycle, from early clinical trials through regulatory approvals.

Product and service7 records
1Biometrics
CategoryBiometrics / Data Management / Statistics
Description

Integrated Biometrics department comprising Data Management, Statistical Analysis and Programming for clinical development. Covers protocol development, CRF development, database design across multiple EDC platforms, CDISC standards (SDTM and ADaM), regulatory submissions, pharmacokinetics/pharmacodynamics analyses using Phoenix WinNonLin, and statistical programming for NDA submissions. For biotech and pharmaceutical sponsors.

2Clinical Operations
CategoryClinical Trial Management
Description

Phase 1 to 4 clinical research services covering project management, project planning (timeline optimization, country selection, feasibility, study start-up, vendor management), clinical monitoring and site management, feasibility assessments, and Trial Master File management via Veeva Vault. For biotech and pharmaceutical sponsors.

3Strategic Consulting
CategoryClinical Development Consulting
Description

Strategic consulting on planning and execution of clinical trials, including experimental design and program optimization for drug development sponsors. For biotech and pharmaceutical companies.

4Medical Writing
CategoryRegulatory and Scientific Writing
Description

Production of high-quality medical documents for drug development sponsors, including clinical study reports, regulatory submissions, publications, and other clinical development documentation with efficient turnaround times.

5Quality Assurance
CategoryQuality Assurance / Compliance
Description

Inspection readiness gap assessment and risk mitigation strategic consulting provided by QA professionals with expertise in regulatory compliance and quality management. For biotech and pharmaceutical sponsors.

6Clinical Drug Safety and Pharmacovigilance
CategoryPharmacovigilance / Drug Safety
Description

Customized drug safety monitoring solutions for evaluation, processing, site interaction, and regulatory reporting using Argus Safety database. Services include safety case processing, risk management, regulatory reports (DSUR, IND annual reports), and drug safety auditing. For biotech and pharmaceutical sponsors.

7Medical Monitoring
CategoryMedical Monitoring
Description

Strategic consulting and medical monitoring services provided by a team of medical experts across multiple therapeutic indications. For biotech and pharmaceutical sponsors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-size, profitable, full-service clinical CRO focused on small/mid-cap biotech and pharma. Closely comparable to InClin in therapeutic breadth, sponsor segment, and integrated Phase 1–4 service model — the relevant public-market benchmark.

TypeDirect peer
Description

Mid-tier global CRO with comparable full-service Phase 1–4 capabilities and strong scientific/medical affairs emphasis. Directly competes for the same small/mid-cap biotech and specialty pharma sponsors as InClin.

TypeDirect peer
Description

Specialty CRO providing full-service clinical development with emphasis on biotech, rare disease, and specialty therapeutic areas. Highly comparable in sponsor segment and mid-tier scale.

TypeDirect peer
Description

PE-backed (KKR) mid-tier full-service CRO with integrated biometrics, clinical operations, and regulatory services. Closely comparable in service mix and biotech sponsor focus; an example of a scaled-up version of InClin's model.

TypeDirect peer
Description

Mid-size, privately-held full-service CRO serving small and mid-sized biopharma with adaptive trial designs and integrated biometrics. Comparable scale, sponsor segment, and ownership profile.

TypeBroad incumbent
Description

One of the top global full-service CROs post-PRA Health acquisition. Overlaps with every InClin service line and increasingly competes for mid-cap biotech business, but operates at vastly larger scale.

TypeBroad incumbent
Description

Largest global CRO and life sciences technology provider with end-to-end Phase 1–4 services, real-world data, and analytics. Represents the upper-bound competitive threat; smaller biotech sponsors often default to IQVIA for integrated programs.

TypeBroad incumbent
TypeBroad incumbent
Description

One of the largest global CROs with full Phase 1–4 services plus central labs — and the historical employer of multiple InClin leaders (e.g., CEO Brian Horger was Director of BD at Covance Early Clinical). Direct talent and capability overlap.

TypeBroad incumbent
Description

Top-tier global CRO (now part of Thermo Fisher Scientific) with full-service Phase 1–4 capabilities. A relevant scale benchmark and direct competitor for mid-cap biotech clinical work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InClin, Inc

Contract Research Organization (CRO) Servicesinclin.com

InClin is a privately-held, full-service Contract Research Organization founded in 1998, providing Phase 1 through Phase 4 clinical research services (biometrics, clinical operations, drug safety, medical writing, QA, and monitoring) to biotech and pharmaceutical sponsors from offices in San Mateo, California and Sydney, Australia.

What InClin, Inc does

InClin, Inc. is a privately-held, full-service Contract Research Organization (CRO) founded in 1998 that delivers clinical research services to biotechnology and pharmaceutical sponsors from Phase 1 through Phase 4. The company operates from a San Mateo, California headquarters and a wholly-owned Australian subsidiary (InClin PTY LTD) in North Sydney, providing regional coverage in North America and the Asia-Pacific. Its customer base spans small biotech startups and enterprise pharmaceutical sponsors, with documented experience executing multinational registrational trials across up to 36 countries and 291 sites, including programs that have achieved NDA and EMA approvals.

The service portfolio covers Biometrics (data management, statistical analysis, CDISC-compliant SDTM/ADaM dataset development, and PK/PD analyses using Phoenix WinNonLin), Clinical Operations (project management, monitoring, feasibility, and Trial Master File management via Veeva Vault), Strategic Consulting, Medical Writing, Quality Assurance, Clinical Drug Safety and Pharmacovigilance (anchored on the Argus Safety database), and Medical Monitoring. The technology stack is built entirely on industry-standard third-party platforms rather than proprietary systems; differentiation is positioned on staff quality (averaging 20+ years of clinical research experience) and a regulatory track record that includes 3 successful NDA approvals and multiple FDA/EMA inspections with no 483 observations.

InClin generates revenue through custom professional services contracts on multi-year engagements. The go-to-market is sales-led, with direct business development outreach, quote-based pricing per engagement, and services contracted either as integrated single-source solutions or as standalone modules. The company is founder-owned: co-founders Arnold G. Wong (CFO) and Taylor T. Kilfoil (Chief International Officer) remain in active leadership roles alongside CEO Brian A. Horger, PhD (formerly of Genentech, Theravance Biopharma, and Covance Early Clinical Services). No external institutional investors, private equity backing, or parent company ownership is indicated in available data.

InClin, Inc firmographics

Firmographics
Name
InClin, Inc
Legal name
InClin, Inc.
Website
https://inclin.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
InClin is a privately-held, full-service Contract Research Organization founded in 1998, providing Phase 1 through Phase 4 clinical research services (biometrics, clinical operations, drug safety, medical writing, QA, and monitoring) to biotech and pharmaceutical sponsors from offices in San Mateo, California and Sydney, Australia.
Ownership category
akta.pro rank

InClin, Inc industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs

Keywords

  • Contract research organization
  • Clinical trial services
  • Biometrics and statistics
  • Pharmacovigilance services
  • Medical writing

Where InClin, Inc is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

InClin, Inc business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Organization Services: InClin generates revenue as a full-service CRO providing integrated clinical research services from Phase 1 through Phase 4. Revenue is derived from service fees for biometrics, clinical operations, strategic consulting, medical writing, quality assurance, drug safety, and medical monitoring services. Services can be contracted as comprehensive single-source solutions or as standalone service modules.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CRO service contracts

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

InClin, Inc product offering

Product offering

Core offering

InClin is a full-service Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to manage Phase 1 through Phase 4 clinical trials. The company delivers integrated single-source solutions or standalone services spanning biometrics, clinical operations, strategic consulting, medical writing, quality assurance, drug safety and pharmacovigilance, and medical monitoring for drug development sponsors.

Product overview

InClin is a full-service Contract Research Organization (CRO) founded in 1998, offering an integrated suite of clinical research services from Phase 1 through Phase 4. The company operates as a single-source solution combining Biometrics, Clinical Operations, Strategic Consulting, Medical Writing, Quality Assurance, Clinical Drug Safety and Pharmacovigilance, and Medical Monitoring services. These core offerings work together as an integrated solution or can be engaged as standalone services to support biotech and pharmaceutical companies through the complete drug development lifecycle, from early clinical trials through regulatory approvals.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biometrics Integrated Biometrics department comprising Data Management, Statistical Analysis and Programming for clinical development. Covers protocol development, CRF development, database design across multiple EDC platforms, CDISC standards (SDTM and ADaM), regulatory submissions, pharmacokinetics/pharmacodynamics analyses using Phoenix WinNonLin, and statistical programming for NDA submissions. For biotech and pharmaceutical sponsors.
  • Clinical Operations Phase 1 to 4 clinical research services covering project management, project planning (timeline optimization, country selection, feasibility, study start-up, vendor management), clinical monitoring and site management, feasibility assessments, and Trial Master File management via Veeva Vault. For biotech and pharmaceutical sponsors.
  • Strategic Consulting Strategic consulting on planning and execution of clinical trials, including experimental design and program optimization for drug development sponsors. For biotech and pharmaceutical companies.
  • Medical Writing Production of high-quality medical documents for drug development sponsors, including clinical study reports, regulatory submissions, publications, and other clinical development documentation with efficient turnaround times.
  • Quality Assurance Inspection readiness gap assessment and risk mitigation strategic consulting provided by QA professionals with expertise in regulatory compliance and quality management. For biotech and pharmaceutical sponsors.
  • Clinical Drug Safety and Pharmacovigilance Customized drug safety monitoring solutions for evaluation, processing, site interaction, and regulatory reporting using Argus Safety database. Services include safety case processing, risk management, regulatory reports (DSUR, IND annual reports), and drug safety auditing. For biotech and pharmaceutical sponsors.
  • Medical Monitoring Strategic consulting and medical monitoring services provided by a team of medical experts across multiple therapeutic indications. For biotech and pharmaceutical sponsors.

Quantifiable outcome

  • 3 successful NDA approvals for Phase 1-3 clinical development programs
  • +3 more outcomes

Companies that use InClin, Inc

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

InClin, Inc technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

InClin, Inc partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights3 records

InClin, Inc competitors and assessment

Company assessment

Direct peers

  • Medpace: Mid-size, profitable, full-service clinical CRO focused on small/mid-cap biotech and pharma. Closely comparable to InClin in therapeutic breadth, sponsor segment, and integrated Phase 1–4 service model — the relevant public-market benchmark.
  • Worldwide Clinical Trials: Mid-tier global CRO with comparable full-service Phase 1–4 capabilities and strong scientific/medical affairs emphasis. Directly competes for the same small/mid-cap biotech and specialty pharma sponsors as InClin.
  • Premier Research: Specialty CRO providing full-service clinical development with emphasis on biotech, rare disease, and specialty therapeutic areas. Highly comparable in sponsor segment and mid-tier scale.
  • Caidya (formerly dMed): PE-backed (KKR) mid-tier full-service CRO with integrated biometrics, clinical operations, and regulatory services. Closely comparable in service mix and biotech sponsor focus; an example of a scaled-up version of InClin's model.
  • Clinipace Worldwide: Mid-size, privately-held full-service CRO serving small and mid-sized biopharma with adaptive trial designs and integrated biometrics. Comparable scale, sponsor segment, and ownership profile.

Broad incumbents

  • ICON plc: One of the top global full-service CROs post-PRA Health acquisition. Overlaps with every InClin service line and increasingly competes for mid-cap biotech business, but operates at vastly larger scale.
  • IQVIA: Largest global CRO and life sciences technology provider with end-to-end Phase 1–4 services, real-world data, and analytics. Represents the upper-bound competitive threat; smaller biotech sponsors often default to IQVIA for integrated programs.
  • Syneos Health:
  • Labcorp Drug Development (formerly Covance): One of the largest global CROs with full Phase 1–4 services plus central labs — and the historical employer of multiple InClin leaders (e.g., CEO Brian Horger was Director of BD at Covance Early Clinical). Direct talent and capability overlap.
  • PPD (Thermo Fisher): Top-tier global CRO (now part of Thermo Fisher Scientific) with full-service Phase 1–4 capabilities. A relevant scale benchmark and direct competitor for mid-cap biotech clinical work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

InClin, Inc social profiles

Digital presence

InClin, Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InClin, Inc leadership team

Management profile

Number of profiles

Profiles9 records

InClin, Inc subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

InClin, Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InClin, Inc M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InClin, Inc

What does InClin, Inc do?

InClin is a full-service Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to manage Phase 1 through Phase 4 clinical trials. The company delivers integrated single-source solutions or standalone services spanning biometrics, clinical operations, strategic consulting, medical writing, quality assurance, drug safety and pharmacovigilance, and medical monitoring for drug development sponsors.

Is InClin, Inc a public or private company?

InClin, Inc is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was InClin, Inc founded?

InClin, Inc was founded in 1998. It employs 101 to 250 people.

Where is InClin, Inc based?

InClin, Inc is headquartered in San Mateo, United States, in the North America region.

How does InClin, Inc make money?

One revenue line is on record: contract Research Organization Services.

Who are InClin, Inc's main competitors?

Direct peers on record are Medpace, Worldwide Clinical Trials, Premier Research, Caidya (formerly dMed) and Clinipace Worldwide. Broad incumbents are ICON plc, IQVIA, Syneos Health, Labcorp Drug Development (formerly Covance) and PPD (Thermo Fisher).

Does InClin, Inc have an API?

No public API is recorded for InClin, Inc.

What industry is InClin, Inc in?

InClin, Inc's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAmplitude Ventures-backed Thryv Therapeutics raises $30 million in Series B led by InClinThryv Therapeutics raised $30 million in Series B financing led by InClin, with participation from Amplitude Ventures. The clinical-stage biotech develops precision therapies for inherited channel disorders, cardiometabolic diseases, and cardiomyopathies. Proceeds will fund ASPIRE-HF, a Phase 2a trial of THRV-1268 in heart failure, opening enrollment in early 2027.BitlyThryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT SyndromeThryv Therapeutics announced a $30 million Series B financing led by InClin, Inc. to advance THRV-1268 into ASPIRE-HF, a Phase 2a heart failure study opening early 2027. Wave II in Long QT Syndrome completed its first efficacy cohort, with data expected in early 2027.NewswireThryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT SyndromeThryv Therapeutics announced a $30 million Series B financing led by InClin, Inc., to advance its SGK1 inhibitor THRV-1268. The funds will support ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction, opening in early 2027, while Wave II in Long QT Syndrome completes its first efficacy cohort with data expected in early 2027.PR NewswireThryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT SyndromeThryv Therapeutics announced a $30 million Series B financing led by InClin, Inc., to advance its SGK1 inhibitor THRV-1268. The funds will support ASPIRE-HF, a Phase 2a heart failure study opening early 2027, while Wave II in Long QT Syndrome completes its first efficacy cohort with data expected early 2027.openPR.comUS Medical Writing Market Grows from USD 1.20B to USD 3.11BThe United States medical writing market is projected to grow from USD 1.20 billion in 2025 to USD 3.11 billion by 2035, expanding at a CAGR of 10.00%. This growth is driven by increasing regulatory documentation requirements, a rising number of clinical trials, and the expansion of the pharmaceutical and biotechnology sectors. Key industry participants include specialized firms such as IQVIA Holdings, Parexel International Corporation, and Inclin, Inc.GlobeNewswireUnited States Medical Writing Market Report 2024-2032, Featuring Profiles of Inclin, Parexel, Cardinal Health, MakroCare, Freyr Solutions, Banner Medical, IQVIA Holdings, Certara and ClinovoThe U.S. medical writing market was valued at $1.09 billion in 2023 and is projected to grow at a 10% CAGR to $2.57 billion by 2032. Growth is driven by R&D activity, FDA regulations, and clinical trial expansion, with challenges including talent shortages and cost constraints.